FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
 announced by Shareholders Foundation - EconoTimes)
SAN DIEGO, Feb. 14, 2017 -- The Shareholders Foundation, Inc. announces that a lawsuit is pending in Colorado on behalf of certain purchasers of shares of Clovis Oncology Inc (NASDAQ:CLVS) over alleged Securities Laws Violations by Clovis Oncology.
Investors who purchased shares of Clovis Oncology Inc (NASDAQ:CLVS) before May 2014 and continue to hold any NASDAQ:CLVS shares have certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
On November 19, 2015, a lawsuit was filed against Clovis Oncology Inc over alleged securities laws violations. The plaintiff claimed that the defendants allegedly made false and misleading statements and/or failed to disclose that the NDA that Clovis submitted to the FDA for rociletinib contained immature data sets based on both unconfirmed response rates and confirmed response rates, that Clovis Oncology’s Breakthrough Therapy designation submission contained immature data sets based primarily on unconfirmed responses, that Clovis Oncology presented interim data publicly and at medical meetings that included a data set based primarily on unconfirmed responses, that as the efficacy data matured, the number of patients with an unconfirmed response who converted to a confirmed response was lower than expected, and that as a result of the foregoing, Clovis Oncology’s NDA was likely to be delayed and/or rejected by the FDA. On July 27, 2016, the defendants filed their motions to dismiss the case. On February 9, 2017, the judge presiding over the case refused to dismiss the lawsuit.
Those who purchased Clovis Oncology Inc (NASDAQ:CLVS) shares should contact the Shareholders Foundation, Inc. by e-mail at [email protected] or call +1 (858) 779-1554.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
CONTACT: Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 [email protected] 3111 Camino Del Rio North Suite 423 San Diego, CA 92108
